Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclotheonamide A is a naturally occurring cyclic peptide isolated from the marine sponge Theonella. It features a unique structure with a cyclic arrangement of amino acids and has attracted interest in medicinal chemistry due to its potential pharmacological properties—including antimicrobial and cytotoxic effects. Cyclotheonamide A is notable for its ability to inhibit specific enzymes and cellular processes; it has been studied as an inhibitor of serine proteases such as trypsin and thrombin by binding to their active sites. Its complex structure contributes to its biological activity but also presents challenges for extraction and synthesis. Cyclotheonamide A remains an experimental compound with no approved clinical indications[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclotheonamide a.